MeiraGTx Holdings plc – NASDAQ:MGTX
MeiraGTx Holdings stock price today
$7.58
+1.37
+22.06%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
MeiraGTx Holdings stock price monthly change
+34.71%
month
MeiraGTx Holdings stock price quarterly change
+34.71%
quarter
MeiraGTx Holdings stock price yearly change
-12.66%
year
MeiraGTx Holdings key metrics
Market Cap | 466.57M |
Enterprise value | 213.32M |
P/E | -1.6 |
EV/Sales | 13.39 |
EV/EBITDA | -1.83 |
Price/Sales | 14.86 |
Price/Book | 2.00 |
PEG ratio | 0.02 |
EPS | -1.27 |
Revenue | 11.38M |
EBITDA | -136.98M |
Income | -74.10M |
Revenue Q/Q | -79.09% |
Revenue Y/Y | -16.45% |
Profit margin | -814.16% |
Oper. margin | -730.87% |
Gross margin | 0% |
EBIT margin | -730.87% |
EBITDA margin | -1203.72% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMeiraGTx Holdings stock price history
MeiraGTx Holdings stock forecast
MeiraGTx Holdings financial statements
| Jun 2023 | 3.54M | -29.58M | -835.62% |
|---|---|---|---|
| Sep 2023 | 5.10M | -44.29M | -868.06% |
| Dec 2023 | 2.04M | 20.21M | 990.93% |
| Mar 2024 | 697K | -20.44M | -2932.86% |
| Mar 2024 | 697K | -20.44M | -2932.86% |
|---|---|---|---|
| Sep 2025 | 50.5M | 25.44M | 50.38% |
| Oct 2025 | 50.5M | 20.18M | 39.96% |
| Dec 2025 | 186.7M | 90.97M | 48.73% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 310263000 | 186.73M | 60.19% |
|---|---|---|---|
| Sep 2023 | 267194000 | 175.30M | 65.61% |
| Dec 2023 | 458168000 | 319.99M | 69.84% |
| Mar 2024 | 309235000 | 187.50M | 60.63% |
| Jun 2023 | -29.01M | -4.97M | 57.94M |
|---|---|---|---|
| Sep 2023 | -24.41M | -3.56M | -404K |
| Dec 2023 | -14.54M | 51.17M | 27.71M |
| Mar 2024 | -36.74M | 27.34M | -1.27M |
MeiraGTx Holdings alternative data
| Aug 2023 | 343 |
|---|---|
| Sep 2023 | 406 |
| Oct 2023 | 406 |
| Nov 2023 | 406 |
| Dec 2023 | 407 |
| Jan 2024 | 407 |
| Feb 2024 | 407 |
| Mar 2024 | 419 |
| Apr 2024 | 419 |
| May 2024 | 419 |
| Jun 2024 | 402 |
| Jul 2024 | 402 |
MeiraGTx Holdings other data
29.85%
-35.45%
of MGTX is owned by hedge funds
51
-44
13.48M
-15.69M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2022 | 5000 | 0 |
| May 2023 | 4347826 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | INDYK MARTIN director | Ordinary Shares | 20,000 | N/A | N/A | ||
Option | INDYK MARTIN director | Restricted Share Units | 20,000 | N/A | N/A | ||
Option | HARRIS KEITH R. director | Ordinary Shares | 30,000 | N/A | N/A | ||
Option | HARRIS KEITH R. director | Restricted Share Units | 30,000 | N/A | N/A | ||
Option | GIROUX RICHARD officer: CFO & COO | Ordinary Shares | 25,000 | N/A | N/A | ||
Option | GIROUX RICHARD officer: CFO & COO | Restricted Share Units | 25,000 | N/A | N/A | ||
Option | ZELDIN ROBERT K officer: CHIEF MEDICAL OFFICER | Ordinary Shares | 37,500 | N/A | N/A | ||
Option | ZELDIN ROBERT K officer: CHIEF MEDICAL OFFICER | Restricted Share Units | 37,500 | N/A | N/A | ||
Option | FORBES ALEXANDRIA director, officer.. | Ordinary Shares | 30,000 | N/A | N/A | ||
Option | FORBES ALEXANDRIA director, officer.. | Restricted Share Units | 30,000 | N/A | N/A |
| Insider | Compensation |
|---|---|
| Dr. Alexandria Forbes (1965) Chief Executive Officer, Pres & Director | $4,300,000 |
Mr. Richard Brian Giroux B.A. (1973) Chief Operating Officer & Chief Financial Officer | $3,790,000 |
| Dr. Stuart Naylor Ph.D. (1963) Chief Devel. Officer | $1,190,000 |
-
What's the price of MeiraGTx Holdings stock today?
One share of MeiraGTx Holdings stock can currently be purchased for approximately $7.58.
-
When is MeiraGTx Holdings's next earnings date?
Unfortunately, MeiraGTx Holdings's (MGTX) next earnings date is currently unknown.
-
Does MeiraGTx Holdings pay dividends?
No, MeiraGTx Holdings does not pay dividends.
-
How much money does MeiraGTx Holdings make?
MeiraGTx Holdings has a market capitalization of 466.57M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 11.95% to 14.02M US dollars.
-
What is MeiraGTx Holdings's stock symbol?
MeiraGTx Holdings plc is traded on the NASDAQ under the ticker symbol "MGTX".
-
What is MeiraGTx Holdings's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of MeiraGTx Holdings?
Shares of MeiraGTx Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are MeiraGTx Holdings's key executives?
MeiraGTx Holdings's management team includes the following people:
- Dr. Alexandria Forbes Chief Executive Officer, Pres & Director(age: 60, pay: $4,300,000)
- Mr. Richard Brian Giroux B.A. Chief Operating Officer & Chief Financial Officer(age: 52, pay: $3,790,000)
- Dr. Stuart Naylor Ph.D. Chief Devel. Officer(age: 62, pay: $1,190,000)
-
How many employees does MeiraGTx Holdings have?
As Jul 2024, MeiraGTx Holdings employs 402 workers, which is 4% less then previous quarter.
-
When MeiraGTx Holdings went public?
MeiraGTx Holdings plc is publicly traded company for more then 7 years since IPO on 8 Jun 2018.
-
What is MeiraGTx Holdings's official website?
The official website for MeiraGTx Holdings is meiragtx.com.
-
Where are MeiraGTx Holdings's headquarters?
MeiraGTx Holdings is headquartered at 430 East 29th Street, New York, NY.
-
How can i contact MeiraGTx Holdings?
MeiraGTx Holdings's mailing address is 430 East 29th Street, New York, NY and company can be reached via phone at +64 6 860 7985.
MeiraGTx Holdings company profile:
MeiraGTx Holdings plc
meiragtx.comExchange:
NASDAQ
Full time employees:
387
Industry:
Biotechnology
Sector:
Healthcare
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
430 East 29th Street
New York, NY 10016
New York, NY 10016
CIK: 0001735438
ISIN: KYG596651029
CUSIP: G59665102
